CHILDHOOD ABSENCE EPILEPSY: RX, PK-PD-PHARMACOGENETICS

儿童失神癫痫：RX、PK-PD-药物遗传学

• 批准号: 7606548
• 负责人: DORIS A TRAUNER
• 金额: $ 3.14万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606548
• 关键词: Absence Epilepsy; Anticonvulsants; Child; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Incidence; Institution; Pharmacogenetics; Rate; Research; Research Personnel; Resources; Seizures; Source; Toxic effect; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To identify the optimal anticonvulsant (i.e. the AED with the highest rate of seizure control and lowest incidence of treatment limiting toxicity) used for the initial treatment of children with Childhood Absence Epilepsy (CAE).

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 确定用于儿童失神癫痫 (CAE) 儿童初始治疗的最佳抗惊厥药物（即癫痫控制率最高且治疗限制毒性发生率最低的 AED）。